Factors associated with low tuberculosis preventive therapy prescription rates among health care workers in rural South Africa

Amiya A. Ahmed*, Megan Grammatico*, Anthony P. Moffet*, Sipho Malinga*, Phillie Makhunga†, Salome Charalamous*, Joseph B. Ladines-Lim *, Justin Jones*, Koeun Choi * and Sheela V. Shenoi *

*Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; †Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA; *Church of Scotland Hospital, Tugela Ferry, South Africa; †Philanjalo NGO, Tugela Ferry, South Africa; *Aurum Institute, Johannesburg, South Africa; Department of Medicine and Pediatrics, Michigan Medicine, Ann Arbor, MI, USA; *Institute of Behavioral Research, Texas Christian University, Fort Worth, TX, USA; Department of Medicine, Yale University School of Medicine, New Haven, CT, USA

ABSTRACT

Background: Despite extensive rollout of tuberculosis preventive therapy (TPT) in South Africa to reduce the incidence of tuberculosis among people living with HIV (PWH), rates of initiation and completion have remained suboptimal.

Objective: This study aimed to identify factors associated with low TPT prescription rates among health care workers (HCWs) in rural South Africa.

Methods: A cross-sectional study was conducted using an anonymous 39-item questionnaire guided by the Consolidated Framework for Implementation Research (CFIR). HCWs from a government district hospital and 14 primary healthcare clinics (PHCs) in the rural Msinga sub-district of KwaZulu-Natal were surveyed from November 2019 to January 2020. Self-reported data on prescription rates as well as knowledge, attitudes, beliefs, and practices regarding isoniazid preventative therapy, the current TPT regimen, were obtained. Factor analysis and logistic regression were used to determine associations with low prescription rates (< 50% of PWH) for TPT prescribers, and results were placed within CFIR-driven context.

Results: Among 160 HCWs, the median (IQR) age was 39 (33–46) years, 76% were women, 78% worked at a PHC, and 44% had experience prescribing TPT. On multivariable analysis, prescribers (n = 71) who believed their patients would not disclose TPT use to others were significantly less likely to prescribe TPT (aOR 4.19 95% CI 1.35–13.00; p = 0.01). Inadequate isoniazid supplies trended towards significance (aOR 10.10 95% CI 0.95–106.92; p = 0.06) in association with low prescription rates.

Conclusions: Strengthening HCW training to emphasize TPT prescription to all eligible PWH regardless of beliefs about patient disclosure and ensuring a consistent isoniazid supply at the health systems-level are both critical steps to enhancing TPT implementation in rural South Africa.

Background

In 2011, the World Health Organization (WHO) released guidelines endorsing the use of tuberculosis preventive therapy (TPT) for preventing tuberculosis in resource-limited settings with high burdens of tuberculosis (TB) and human immunodeficiency virus (HIV) infection [1]. The government of South Africa quickly adopted these guidelines in its own policy to increase uptake of TPT and ease the country’s burden of TB and HIV [2], which is among the highest in the world [3,4]. However, while South Africa has led global implementation, rates of both initiation and completion of TPT have remained low [5,6]. In 2019, nearly a decade after TPT implementation in South Africa, only 69% of newly enrolled HIV-positive patients in South Africa were prescribed TB preventive treatment (TPT) [3,7], which falls short of the expectations of the current South African guidelines that state all new eligible people living with HIV (PWH) are expected to receive TPT immediately alongside antiretroviral therapy (ART) initiation [2].

Several studies have investigated the factors associated with TPT implementation among patients and community members [8,9]. Among PWH in rural KwaZulu-Natal, South Africa, self-reported barriers include poor understanding of TPT’s preventative role, inefficiencies during the prescription process, and the cost of transportation and opportunity cost of lost wages. Conversely, adequate knowledge of TB and TPT, acceptance of one’s HIV diagnosis, social support in the community, and the ability to...
communicate comfortably with a health care worker (HCW) were all identified as facilitators [8]. Elsewhere in KwaZulu-Natal Province, South Africa, TPT was perceived by community members to be dangerous because of the unsustainable costs, stigma of pill consumption, and the belief that it introduced excess dirt or toxins, locally referred to as ukungcola, into the body [9].

Few studies have investigated the facilitators and barriers to TPT implementation from the perspective of HCWs. In Gauteng Province, South Africa, a qualitative study found that HCWs reported the primary barrier to TPT implementation was HCW knowledge regarding TPT. While all doctors in the study had heard of TPT, there were many who were either unfamiliar with or in disbelief of its efficacy in preventing TB [10], resulting in limited TPT use. In a more recent South African study, nurses were placed in a clinical mentorship program to improve TPT prescription rates. Participants from this study reported high adoption and acceptability of TPT, but identified that national TPT guidelines were a significant barrier to TPT initiation due to their ambiguous nature [11]. A quantitative multi-site, cross-sectional study conducted in Ethiopia found that a clinician’s perception that active TB was difficult to rule out was independently and inversely associated with high TPT rates [12].

The Consolidated Framework for Implementation Research (CFIR) is an established implementation science framework for assessing health interventions within the appropriate context. Contextual factors may influence either delivery, outcomes, or how the interventions perform and are critical to understanding how to strengthen implementation. CFIR’s core constructs provide a roadmap for evaluating all aspects of implementation within five major domains, including 1) the ‘intervention’, 2) ‘individuals’, 3) ‘inner setting’, 4) ‘outer setting’, and 5) the ‘processes’ of delivery [13]. All of the barriers mentioned in the previous paragraphs would fall into one of these five domains. For example, gaps in knowledge regarding TPT may fall within the ‘individual’ domain, while the distance from a patient’s home to the clinic could fall within the ‘outer setting’ domain. By recognizing the context from which these facilitators and barriers emerge, a broader framework can be established to improve implementation.

Therefore, in the context of suboptimal TPT implementation in South Africa, previous evaluations of patients’ perspectives, and the limited number of studies investigating HCW-related associations with low TPT rates, we sought to use CFIR to examine the factors associated with low TPT prescription rates among HCWs in the rural Msinga municipality of KwaZulu-Natal, South Africa.

**Methods**

**Study setting**

The rural Msinga municipality in KwaZulu-Natal, South Africa has a total area of ~2500 square kilometers and is home to a population of nearly 180,000 traditional Zulu people [14]. The municipality is among the poorest in the nation with high rates of unemployment (85%) and nearly 50% of the population lacking access to electricity [15]. The region is characterized by a high TB incidence (> 1100/100,000) and HIV antenatal prevalence (31.1%) [6], and 94.2% of TB/HIV co-infected clients are on ART [16]. A government district hospital and 16 satellite primary health care clinics (PHCs), run by senior level professional nurses who have prescribing capacity, provide free primary care services, including ART and TPT to HIV-positive patients in the sub-district [8,15,16]. While TPT may refer to various TB preventive regimens, the only option for TPT at the time of this study was 6–12 months of daily isoniazid, which has been implemented since May 2010 [2].

**Study participants and study period**

Health-care workers (HCWs), ≥18 years of age who worked in a public-sector health facility in the Msinga sub-district with direct patient care responsibilities, were included in the study. Potential participants were recruited at clinic staff meetings November 2019 to January 2020. All clinic site visits were scheduled in advance with and approved by the operational manager of each individual clinic.

**Definitions**

**Direct TPT providers**

Direct TPT providers were defined as medical officers, professional nurses, and staff nurses who self-identified by providing a positive response to the survey question: ‘Do you have experience prescribing TPT?’ These HCWs were involved in identifying eligible patients and/or prescribing TPT. Medical officers have a MBBCH, MBBS, or MD/DO degree and are registered with the Health Professions Council of South Africa, professional nurses have a baccalaureate degree in nursing and are registered with the South African Nursing Council, and staff nurses have a college diploma in nursing. Of note, staff nurses are not allowed to sign a prescription, but are heavily involved in the multistep process of TPT initiation.

**Indirect TPT providers**

Indirect TPT providers were defined as all other participants in our study who did not fit the definition of a direct TPT provider. The participants included
professional nurses, staff nurses, voluntary counseling and testing (VCT) counselors, and other clinicians who provided a negative response to the above question. Of note, the few participants who self-identified as a prescriber, but did not identify as a medical officer, professional nurse, or staff nurse were defined as an indirect TPT provider. The participants may screen, educate, and counsel patients about preventive therapy.

**Data collection**

An anonymous, 39-question survey tool was used to collect self-reported data. There were six questions about demographics, and 33 questions about knowledge, and perceptions regarding HIV and TB, as well as pre-existing knowledge, attitudes, practices, and beliefs towards isoniazid preventive therapy, the current TPT regimen. The survey included ‘Yes/No/Unsure’ questions as well as Likert scale items with the following possible answer choices: (1) ‘A great deal/A lot/Some/A little/Nothing’ or (2) ‘Every patient/More than half of my patients/Less than half of my patients/Never/Declined to Answer’. The survey tool explored all five CFIR domains [13]. The survey tool was made available in English and isiZulu. A copy of the survey tool has been included in Appendix 1.

**Outcome**

The outcome in this study was a low TPT prescription rate, which was defined as prescribing to < 50% of eligible PWH. Our outcome was defined retrospectively using Question 12 in the survey tool (Supplemental Information Item 1).

**Data analysis**

Exploratory factor analysis (EFA) was performed six times separately on the six domains of the survey in order to reduce the number survey items for more concise analysis and discussion. Baseline characteristics and EFA-generated bivariate scores were compared between indirect and direct TPT providers using Pearson’s Chi-square analysis and Mood’s median test, as appropriate. Unadjusted binary logistic regression was used to calculate odds ratios for each factor independently to estimate associations with the outcome of interest. A multivariable binary logistic regression model adjusting for potential predictors was then constructed, including all statistically significant co-variates from the univariate analysis. Statistical tests were two-tailed with 95% confidence intervals. P-values < 0.10 were considered significant for univariate analysis to ensure a broad range of factors were being considered. A stricter p-value cutoff of < 0.05 was considered significant for final multivariate analyses. SPSS 25 for Windows (2017; Armonk, NY: IBM Corp.) was used for all data analyses.

**Defining scales and scores**

For each factor extracted, a 2 to 4-item scale was generated, based on the number of questions that contributed to the factor. For example, a 4-item ‘perceived patient stigma towards IPT’ scale (values 0–4) was initially created. Next, from each scale, a bivariate score was created. Therefore, from our above scale, a ‘perception of increased patient stigma towards IPT’ score was defined as having a value of > 0. This was performed for all 13 factors. A list with the exact question contributions to each individual factor is included in the Supplemental Information Item 1.

**Ethics approval**

The study protocol was approved by the Yale University’s Human Investigation Committee and the University of KwaZulu-Natal Biomedical Research Ethics Committee.

**Results**

**Descriptive characteristics**

There were 160 HCWs in our study with a median (±IQR) age of 39 (±13) years, 76% were women, and...
44% were direct TPT providers (Table 1). The majority (78%) were from a primary health care clinic as opposed to the district hospital. Direct TPT providers were more likely to be older and either a professional nurse or a medical officer.

**Exploratory factor analysis**

Factor analysis was performed separately on the six domains from the survey. Variable reduction was carried out using principal axis factoring and orthogonal varimax rotation with Kaiser Normalization. KMO’s and Bartlett’s test were used to determine if EFA was appropriate. Factors extracted had eigenvalues > 1 and communalities > 0.50. Aside from one item used as the outcome, 32 survey items were reduced to a total of 13 factors as seen in Figure 1.

**Knowledge, attitudes, and beliefs of direct TPT providers**

Regarding knowledge, the majority (90%) of direct TPT providers (n = 71) self-reported knowing ‘a lot’ or ‘a great deal’ about TPT (Table 2). However, a smaller majority (54%) answered objective questions correctly when tested on current South African TPT guidelines. In terms of attitudes, nearly all (99%) had a positive attitude concerning the effectiveness of TPT. However, that did not rule out having concerns as well as some negative attitudes towards TPT among study participants.

**Univariate associations with low TPT prescription rates**

Among direct TPT prescribers (n = 71), none of the descriptive characteristics, including age, sex, length of time practicing as a HCW, or years managing PWH, were associated with low prescription rates. While poor objective knowledge of TPT-related guidelines had no association, poor self-reported knowledge did trend towards significance (p = 0.06). A perception among health workers of poor patient comfort with TPT disclosure (p = 0.01), insufficient TPT training (p = 0.04), and inadequate isoniazid supplies (p = 0.04) were significantly associated with lower prescription rates (Table 3). On the other hand, HCWs’ attitudes concerning TPT and

---

**Table 2. Knowledge, attitudes, and beliefs among direct TPT providers (n = 71).**

| Themes                                      | Factors                                                                 | Frequency, % (n/N) |
|---------------------------------------------|-------------------------------------------------------------------------|--------------------|
| I. HCW Knowledge of TPT                     | Good self-reported TPT knowledge                                        | 90.0% (63/70)      |
|                                             | Good knowledge of TPT guidelines                                        | 53.7% (36/67)      |
| II. HCW Beliefs on Patient Stigma concerning TPT | Perception of increased patient stigma towards TPT                     | 60.0% (42/70)      |
|                                             | Perception of poor patient comfort with TPT disclosure                  | 60.6% (43/71)      |
| III. HCW Attitudes concerning TPT           | Concern about TPT adverse events                                        | 77.5% (55/71)      |
|                                             | Positive attitude towards TPT                                           | 98.6% (68/69)      |
|                                             | Negative attitude towards TPT                                           | 62.9% (44/70)      |
| IV. HCW Beliefs on Patient Factors concerning TPT | Good patient knowledge of TPT                                          | 88.6% (62/70)      |
|                                             | Good patient attitude & practices towards TPT                          | 90.1% (64/71)      |
| V. Organizational Level Factors concerning TPT | Sufficient training to counsel patients on TPT                         | 81.7% (58/71)      |
|                                             | Sufficient time to counsel on TPT                                       | 95.8% (68/71)      |
|                                             | Sufficient isoniazid supply                                             | 93.0% (66/71)      |

---

**Figure 1.** Flowchart of factors generated by exploratory factor analysis (EFA) of survey questions.
patient factors concerning TPT had no association with lower TPT prescription rates.

**Multivariate associations with low TPT prescription rates**

After multivariable adjustment, only one factor was significantly associated with low prescription rates (Table 3). Direct TPT providers who perceived their patients to have poor disclosure of TPT use were approximately four times more likely to have a low prescription rate, defined as prescribing TPT to < 50% of their patients. Of note, inadequate supplies of isoniazid trended towards significance in the multivariate model (aOR 10.10 95% CI 0.95–106.92; p = 0.06).

**Findings within the context of the CFIR model**

Within the CFIR framework, our results highlight two of the five major domains: the outer setting and the characteristics of individuals involved (Figure 2). The perception of HCWs regarding patient comfort with TPT-use disclosure is a modifiable factor at the individual level. On the other hand, the inadequate resources in regards to TPT, including insufficient isoniazid, demonstrates room for improvement at the level of the outer setting in regards to TPT implementation.

**Discussion**

To the best of our knowledge, this is the first study to quantitatively examine HCW-related factors associated with low TPT prescription rates in rural South Africa. We identified that perception of patient willingness to disclose use of TPT influenced HCWs’ likelihood of prescribing TPT to the majority of their patients. Furthermore, the data suggested that HCWs’ belief that isoniazid is not always readily available also affected TPT prescription rates in our study. These findings are important as they provide necessary insight regarding potential areas of improvement at the provider and organizational levels for successful TPT implementation in a rural setting.

In our study, we found that prescribers who believed their patients were unlikely to disclose their TPT use had significantly lower prescription rates of TPT. The effect of disclosure on adherence to HIV care has been well documented in the literature [17,18]. Disclosure of HIV status has been shown to contribute to ART adherence through improving social support, financial support, and reductions in
anxiety and depression, among other mechanisms [17]. HIV-related stigma has been strongly linked to fear of TPT disclosure and TPT-related stigma [8,13,19–21]. To that end, studies in Eswatini and South Africa have found disclosure of HIV status to also improve TPT adherence through mechanisms similar to those stated above [19,20]. While there are fewer such studies focusing on disclosure of TPT use in particular, Adams et al. determined that disclosure of TPT improved TPT completion in Eswatini [17]. Participants in their 2019 study reported that TPT disclosure supported adherence through medication reminders from family members and being able to openly take their medications [17]. To our knowledge, there are no studies documenting the association between HCW perception of patient disclosure and TPT prescription rates. However, previous studies from Ethiopia and South Africa have shown that the fear of generating isoniazid resistance secondary to poor patient adherence were primary reasons HCWs were reluctant to offer TPT [11,22]. While it is possible that fear of TB drug resistance secondary to the suspicion of poor patient disclosure contributes to low prescription rates in this study, only a quarter of prescribers in our study expressed concerns for TB drug resistance due to TPT use. Further investigations are necessary to clarify the reasons behind concerns about disclosure including the potential role of stigma among health care workers.

Additionally, while isoniazid supply shortages were only trending towards significance in association with low prescription rates, nearly a quarter of our participants reported not having TPT medications available when needed. This is in line with the current literature, as limited isoniazid supplies are well documented as a barrier to TPT implementation [22–24]. A 2020 multi-site study in Nigeria identified stockouts of isoniazid as a reason for low TPT uptake and suggested the need for strengthening drug supply logistics in order to optimize TPT uptake [23]. Isoniazid stockouts serve as a two-fold barrier. First, the obvious absence of medications prevents HCWs from supplying their patients with TPT. Second, a lack of certainty in having an uninterrupted supply of isoniazid has an added effect of generating HCW fear of creating isoniazid resistance [22]. Though fear of isoniazid resistance was incorporated into our ‘negative attitude towards TPT’ score, which had no association with low TPT prescription rates, it is still worth noting 25.4% (18/71) direct TPT providers had a fear of TB resistance as a result of TPT. Therefore, appropriate capacity building to address inconsistencies in the supply of isoniazid may be needed to improve confidence among HCWs and increased prescription.

Context is a key component of evaluation implementation, and placing these two factors within a theoretical framework, such as the CFIR model shown in Figure 2, enables us to bridge data to

---

**Figure 2.** CFIR model of TPT implementation in rural South Africa. Domains most likely to benefit from further refinement are marked with yellow stars (adapted from Damschroder et al.).
motivating behavioral change through potential health policy implementation [20]. As mentioned, our study identifies two specific levels for change. At the individual level, while HCWs should endorse patients’ disclosure of their health status to facilitate social support, it is critical to support HCWs in prescribing TPT to all eligible PWH regardless of beliefs about patient disclosure as TPT is a lifesaving tool [21]. At the level of the outer setting, policymakers should ensure a consistent supply of isoniazid. In this rural part of South Africa, these were the two most pertinent domains to improving implementation, and changes at both levels are necessary to successfully strengthen TB prevention health systems. Though not significantly associated with TPT prescription rates on adjusted analyses, it is prudent for policymakers to also ensure robust HCW training and public health education about TPT for patients and community members given its demonstrated mortality benefit independent of ART.

It is worth noting factors that have been found to be significant in previous studies, and which were also included in our study but not found to be associated with poor TPT prescription rates. Both a lack of TPT knowledge and training have been found to be associated on unadjusted analysis with poor practices regarding TPT provision among clinicians in urban South Africa and Nigeria [25–27]. Similarly in our rural study, poor HCW knowledge and training were associated with low prescription rates on univariate analysis, but not identified as barriers after adjusted analysis. Furthermore, evidence has demonstrated that direct providers’ attitudes influence their practices concerning TPT [11,25]. While we found that providers’ attitudes did not impact prescription rates, our study did align with the literature demonstrating that HCWs generally found TPT effective and endorsed TB prevention [17,25,27].

Several limitations of this study must be acknowledged. First, selection bias may have been present as clinics were visited at select times as determined by the operational managers to avoid unnecessary interference with clinical duties. Information bias may have also been present due to missing data as not all participants completed the survey in its entirety. Next, while these findings should be confirmed in a larger sample of HCWs, these findings provide important insight into factors influencing TPT implementation and warrant further evaluation of this critical context. Another limitation was that TPT prescribers as a group were not defined in the traditional sense, and also included staff nurses as they played a key role in TPT initiation. The inclusion of staff nurses in the prescriber group had the potential to attenuate differences observed between prescribers and non-prescriber groups. However, this was not observed, which in fact further strengthens these findings. Additionally, these findings are relevant to primary care clinics in rural resource-limited settings and may not be generalizable to urban areas or other types of health care facilities. Lastly, it is possible that these findings may not be applicable to use of emerging shorter course TPT regimens.

Conclusion

Supporting HCWs at the individual level to expand TPT prescription, regardless of beliefs about patient disclosure, is critical to implementation. Addressing inconsistencies in the isoniazid supply chain at the health systems-level is also necessary to influence successful implementation of TPT.

Acknowledgments

We would like to acknowledge Dr. Gerald Friedland for his support. We thank the Department of Health of the Republic of South Africa for their support of this work and their dedication to patient care.

Author contributions

Amiya A. Ahmed – data acquisition, analysis, interpretation of data, drafting, final approval
Megan Grammatico – data acquisition, interpretation of data, drafting, final approval
Anthony P. Moll – design of work, interpretation of data, drafting, final approval
Sipho Malinga – data acquisition, final approval
Philile Makhunga – data acquisition, drafting, final approval
Salome Charalambous – interpretation of data, drafting, final approval
Joseph B. Ladines-Lim – analysis, drafting, final approval
Koeun Choi – design of work, drafting, final approval
Sheela V. Shenoi – design of work, analysis, interpretation of data, drafting, final approval

Disclosure statement

The authors declare they have no competing interests. SVS’s spouse worked for Merck Pharmaceuticals 1997–2007 and retains company stock in his retirement account.

There is no conflict of interest regarding this manuscript, but it is included for full disclosure.

The data presented in this manuscript has been presented in part at the Infectious Disease Society of America annual meeting, Virtual, October 2020 and the Dissemination and Implementation in Health annual meeting, Virtual, December 2020.

Ethics and consent

This project was approved by the Yale University’s Human Investigation Committee and the University of KwaZulu-Natal Biomedical Research Ethics Committee.
Funding information

This work was supported by the Doris Duke Charitable Foundation #2016178 (AA, KC) and #201516 (SVS); and the Yale International Downs Fellowship #731001 (JJ); and by NIH Fogarty Center #TW010540 (MG); and Yale School of Medicine Short-Term Research Fellowship (JBL); Fogarty International Center #TW010540; Yale School of Public Health Downs Fellowship #731001.

Paper context

TB preventive therapy has been shown to reduce mortality among people living with HIV, independent of antiretroviral therapy. However, global implementation lags. Using a validated implementation science framework, this study demonstrates health care workers who believe their patients do not disclose use of TB preventive therapy were significantly less likely to prescribe it, which is modifiable. Therefore, strengthening health care worker training to facilitate prescribing preventive therapy to all eligible patients is critical to implementation efforts.

ORCID

Amiya A. Ahmed http://orcid.org/0000-0002-2899-9704  
Joseph B. Ladines-Lim http://orcid.org/0000-0002-2461-2752  
Koeun Choi http://orcid.org/0000-0003-2740-9634  
Sheela V. Shenoi http://orcid.org/0000-0001-7654-4344

References

[1] Latent tuberculosis infection: updated and consolidated guidelines for programmatic management [Internet]. World Health Organization; 2018 [cited 2021 Jul 25]. Available from: https://apps.who.int/iris/handle/10665/260233
[2] Guidelines for tuberculosis preventive therapy among HIV-infected individuals in South Africa [Internet]. South Africa Department of Health; 2010 [cited 2021 Jul 25]. Available from: https://www.who.int/hiv/pub/guidelines/south_africa_hiv_tb.pdf
[3] Global tuberculosis report 2020 [Internet]. World Health Organization; 2020 [cited 2021 Jul 25]. Available from: https://www.who.int/tb/publications/global_report/en/
[4] UNAIDS data 2019 [Internet]. UNAIDS; 2019 [cited 2021 Jul 25]. Available from: https://www.unaids.org/en/resources/documents/2019/UNAIDS-data
[5] Chehab JC, Vilakazi-Nhlapo K, Vranken P, et al. Survey of isoniazid preventive therapy in South Africa, 2011. Int J Tuberc Lung Dis. 2012;16:903–907. PubMed PMID: 22583688.
[6] Codecasa LR, Murgia N, Ferrarese M, et al. Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis. 2013;17:903–908. PubMed PMID: 23651743.
[7] Global tuberculosis report 2019 [Internet]. World Health Organization; 2019 [cited 2021 Jul 25]. Available from: https://www.who.int/tb/publications/global_report/en/
[8] Jacobson KB, Niccolai L, Mtungwa N, et al. “It’s about my life”: facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2017;29:936–942. PubMed PMID: 28147705; PubMed Central PMCID: PMC5545149.
[9] Boffa J, Mayan M, Ndlovu S, et al. When prevention is dangerous: perceptions of isoniazid preventive therapy in KwaZulu-Natal, South Africa. Public Health Action. 2019;9:24–31. PubMed PMID: 30963039; PubMed Central PMCID: PMC6436494.
[10] Lester R, Hamilton R, Charalambous S, et al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS. 2010;24:S45–8. PubMed PMID: 21079427.
[11] Jarrett BA, Wozniacz DM, Tilchin C, et al. Promoting tuberculosis preventive therapy for people living with HIV in South Africa: interventions Hindered by complicated clinical guidelines and imbalanced patient-provider dynamics. AIDS Behav. 2020;24:1106–1117. PubMed PMID: 31549265; PubMed Central PMCID: PMC7085432.
[12] Lai J, Dememew Z, Jerene D, et al. Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2019;23:371–377. PubMed PMID: 30871669; PubMed Central PMCID: PMC6822021.
[13] Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. PubMed PMID: 19664226; PubMed Central PMCID: PMC2736161.
[14] Mid-year population estimates 2015 [Internet]. Department of Statistics South Africa; 2016 [cited 2021 Jul 25]. Available from: https://www.statssa.gov.za/publications/P0302/P03022015.pdf
[15] Shenoi SV, Moll AP, Brooks RP, et al. Integrated tuberculosis/human immunodeficiency virus community-based case finding in rural South Africa: implications for tuberculosis control efforts. Open Forum Infect Dis. 2017;4:oof092. PubMed PMID: 28695145; PubMed Central PMCID: PMC5499582.
[16] Massyn N, Pillay Y, Padarath A. District health barometer 2017/18 [Internet]. Health Systems Trust; 2019 [cited 2021 Jul 25]. Available from: https://www.hst.org.za/publications/District%20Health%20Barometers/DHB+2017-18+Web+8+Apr+2019.pdf
[17] Adams LV, Maseko TSB, Talbot EA, et al. Integrated and patient-selected care facilitates completion of isoniazid preventive therapy in Eswatini. Public Health Action. 2019;9:153–158. PubMed PMID: 32042607; PubMed Central PMCID: PMC6945734.
[18] Bulali RE, Kibusi SM, Mpondon BCT. Factors associated with HIV status disclosure and its effect on treatment adherence and quality of life among children 6–17 years on antiretroviral therapy in Southern Highlands Zone, Tanzania: unmatched case control study. Int J Pediatr. 2018;2018:8058291. PubMed PMID: 30046314; PubMed Central PMCID: PMC6038591.
[19] Grande SW, Adams LV, Maseko TSB, et al. The social implications of participant choice on adherence to isoniazid preventive therapy (IPT): a follow-up study
to high completion rates in Eswatini. PLoS One. 2020;15:e0232841. PubMed PMID: 32469990; PubMed Central PMCID: PMC7259658.

[20] Rowe KA, Makhubele B, Hargreaves JR, et al. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis. 2005;9:263–269. PubMed PMID: 15786888.

[21] Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014 Aug 23;384:682–690. PMID: 24835842; PMCID: PMC4233253.

[22] Teklay G, Teklu T, Legesse B, et al. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16:840. PubMed PMID: 27543096; PubMed Central PMCID: PMC4992328.

[23] Yunusa F, Bello M, Kayode GA, et al. Uptake of tuberculosis prevention therapy in people living with HIV/AIDS in northern Nigeria: a programme to increase use of isoniazid preventive therapy. Lancet Glob Health. 2020;8:S37.

[24] Reddy MM, Thekkur P, Ramya N, et al. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action. 2020;13:1704540. PubMed PMID: 31937200; PubMed Central PMCID: PMC7006687.

[25] Van Ginderdeuren E, Bassett J, Hanrahan C, et al. Health system barriers to implementation of TB preventive strategies in South African primary care facilities. PLoS One. 2019;14:e0212035. PubMed PMID: 30763378; PubMed Central PMCID: PMC6375590.

[26] Mindachew M, Deribew A, Memiah P, et al. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;17. PubMed PMID: 24932337; PubMed Central PMCID: PMC4048699. DOI:10.11604/pamj.2014.17.26.2641

[27] Abdurulazaak A, Govender I, Nzaumvila D. Knowledge, attitudes and practices of doctors regarding isoniazid preventive therapy in HIV/AIDS patients at Odi District Hospital, Gauteng province, South Africa. S Afr J Infect Dis. 2018;1–11. DOI:10.1080/23120053.2018.1548726

GLOBAL HEALTH ACTION